![garrido pilar](/var/esmo/storage/images/media/esmo/profiles/garrido-pilar/1820849-3-eng-GB/garrido-pilar.jpg)
Pilar Garrido
Madrid
Spain
Pilar Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá (Madrid, Spain) and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain.
Co-director of the Cancer and Chronic Disease Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), her main areas of research and clinical interest are thoracic tumours, in particular multimodality management, predictive biomarkers, immunotherapy and new anticancer agents in lung cancer. Dr. Garrido is in charge of teaching and patients care and is also actively involved in a number of phase I-III lung cancer clinical trials. Active member of CiberOnc, a Spanish Ministry of Health Network of clinical and translational research, she is building a translational program in collaboration with other clinical and experimental biology Spanish cancer groups. Author of several peer-reviewed manuscripts and book chapters, she serves on the Editorial Board of different journals and has presented her work nationally and internationally.
President of FACME (Spanish Federation of Medical Societies), she was the first woman President of the Spanish Medical Oncology Society. She currently participates on a variety of national scientific committees and is engaged with Spanish National Political and Administrative Institutions. Dr. Garrido is a member of the Spanish National Cancer Strategy Committee, former President of the Minister of Health advisory council and the Medical Oncology Specialty Training Committee.
Member of the ESMO Council and Chair of the Women for Oncology Committee, she also serves as a member of the ESMO Fellowship Committee, Press and Media Affairs Committee and the Leadership Generation Task Force. She is also Associate Editor of Annals of Oncology and a member of the ESMO Faculty for lung and other thoracic tumours.